Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Off-Label Debate Between FDA, Industry To Formally Begin After Election

Executive Summary

After years of industry prodding, FDA schedules a two-day public meeting in November to establish direction for off-label regulation, but the agency is already being pulled in multiple directions.

You may also be interested in...



Off-Label Compendia Weaknesses Illustrated By Tarceva Evidence Gaps

Compendia are often critical to reimbursement for oncology sponsors, but University of North Carolina researchers argue in JAMA the system needs to be revamped.

FDA Taps NIH Veteran Corrigan-Curay To Lead Medical Policy Office

Jennifer Corrigan-Curay joins from the National Heart, Lung and Blood Institute, where she worked on clinical trial initiatives and served as an NIH representative on FDA’s Drug Safety Oversight Board.

Industry's Off-Label Hearing Priorities Taking Shape

Pfizer attorney raises impact on research and other key themes for the upcoming FDA public hearing.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel